Free Trial
NASDAQ:CARA

Cara Therapeutics (CARA) Stock Price, News & Analysis

Cara Therapeutics logo

About Cara Therapeutics Stock (NASDAQ:CARA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$13.29
$17.10
52-Week Range
N/A
Volume
237,144 shs
Average Volume
22,209 shs
Market Capitalization
$24.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
5th Percentile Overall Score

CARA MarketRank™: 

Cara Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 932nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Cara Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for CARA.
  • Dividend Yield

    Cara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CARA.
  • Search Interest

    Only 1 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Cara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cara Therapeutics' insider trading history.
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Cara Therapeutics board approves 1-for-3 reverse stock split
See More Headlines

CARA Stock Analysis - Frequently Asked Questions

Cara Therapeutics, Inc. (NASDAQ:CARA) announced its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share for the quarter, missing the consensus estimate of ($9.72) by $3.60. The biopharmaceutical company earned $0.99 million during the quarter, compared to analyst estimates of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%.

Shares of Cara Therapeutics reverse split on Wednesday, April 16th 2025.The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

Last Earnings
8/14/2024
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARA
CIK
1346830
Employees
80
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($21.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.51 million
Net Margins
-1,099.76%
Pretax Margin
-1,099.76%
Return on Equity
-367.97%
Return on Assets
-107.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.77
Quick Ratio
4.71

Sales & Book Value

Annual Sales
$7.14 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,574,000
Free Float
4,429,000
Market Cap
$24.33 million
Optionable
Optionable
Beta
0.41

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CARA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners